Search

Your search keyword '"Bohm, M"' showing total 717 results
Start Over Author "Bohm, M"
717 results on '"Bohm, M"'

103. Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future

Author

Mahfoud, F., Schmieder, R.E., Azizi, M., Pathak, A., Sievert, H., Tsioufis, C., Zeller, T., Bertog, S., Blankestijn, P.J., Bohm, M., Burnier, M., Chatellier, G., Zaleski, I. Durand, Ewen, S., Grassi, G., Joner, M., Kjeldsen, S.E., Lobo, M.D., Lotan, C., Luscher, T.F., Parati, G., Rossignol, P., Ruilope, L., Sharif, F., Leeuwen, E. van, Volpe, M., Windecker, S., Witkowski, A., Wijns, W., Mahfoud, F., Schmieder, R.E., Azizi, M., Pathak, A., Sievert, H., Tsioufis, C., Zeller, T., Bertog, S., Blankestijn, P.J., Bohm, M., Burnier, M., Chatellier, G., Zaleski, I. Durand, Ewen, S., Grassi, G., Joner, M., Kjeldsen, S.E., Lobo, M.D., Lotan, C., Luscher, T.F., Parati, G., Rossignol, P., Ruilope, L., Sharif, F., Leeuwen, E. van, Volpe, M., Windecker, S., Witkowski, A., and Wijns, W.

Abstract

Contains fulltext : 182378.pdf (Publisher’s version ) (Open Access)

Published
2017

105. Identification of a specific pattern of downregulation in expression of isoforms of vascular endothelial growth factor in dilated cardiomyopathy. (Scientific Letter)

Author

Boer, R.A. De, Henning, R.H., Tio, R.A., Pinto, Y.M., Brouwer, R.M.H.J., Ploeg, R.J., Bohm, M., Gilst, W.H. Van, and Veldhuisen, D.J. Van

Subjects
Cardiomyopathy, Dilated -- Physiological aspects, Vascular endothelial growth factor -- Physiological aspects, Health, Physiological aspects
Abstract

Recent work suggests that myocardial hypoxia or ischaemia are also pathophysiologic factors in idiopathic dilated cardiomyopathy (IDC). (1) Besides several other factors (increased wall stress, endothelial dysfunction, decreased coronary reserve), [...]

Published
2002

106. Predicting wind flow in fragmented forested landscapes

Author

Poette, Christopher, Gardiner, Barry A., Dupont, Sylvain, Brunet, Yves, Harman, Ian N., Bohm, M., Finnigan, John J., Hugues, D., Interactions Sol Plante Atmosphère (UMR ISPA), Institut National de la Recherche Agronomique (INRA)-Ecole Nationale Supérieure des Sciences Agronomiques de Bordeaux-Aquitaine (Bordeaux Sciences Agro), Commonwealth Scientific and Industrial Research Organisation [Canberra] (CSIRO), Australian Meteorological and Oceanographic Society, Partenaires INRAE, and ProdInra, Migration

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2016

107. Predicting heart failure outcome from cardiac and comorbid conditions: The 3C-HF score

Author

Senni, M, Parrella, P, De Maria, R, Cottini, C, Bohm, M, Ponikowski, P, Filippatos, G, Tribouilloy, C, Di Lenarda, A, Oliva, F, Pulignano, G, Cicoira, M, Nodari, S, Porcu, M, Cioffi, G, Gabrielli, D, Parodi, O, Ferrazzi, P, Gavazzi, A, Senni M, Parrella P, De Maria R, Cottini C, Bohm M, Ponikowski P, Filippatos G, Tribouilloy C, Di Lenarda A, Oliva F, Pulignano G, Cicoira M, Nodari S, Porcu M, Cioffi G, Gabrielli D, Parodi O, Ferrazzi P, Gavazzi A, Senni, M, Parrella, P, De Maria, R, Cottini, C, Bohm, M, Ponikowski, P, Filippatos, G, Tribouilloy, C, Di Lenarda, A, Oliva, F, Pulignano, G, Cicoira, M, Nodari, S, Porcu, M, Cioffi, G, Gabrielli, D, Parodi, O, Ferrazzi, P, Gavazzi, A, Senni M, Parrella P, De Maria R, Cottini C, Bohm M, Ponikowski P, Filippatos G, Tribouilloy C, Di Lenarda A, Oliva F, Pulignano G, Cicoira M, Nodari S, Porcu M, Cioffi G, Gabrielli D, Parodi O, Ferrazzi P, and Gavazzi A

Abstract

Background: Prognostic stratification in heart failure (HF) is crucial to guide clinical management and treatment decision-making. Currently available models to predict HF outcome have multiple limitations. We developed a simple risk stratification model, based on routinely available clinical information including comorbidities, the Cardiac and Comorbid Conditions HF (3C-HF) Score, to predict all-cause 1-year mortality in HF patients. Methods: We recruited in a cohort study 6274 consecutive HF patients at 24 Cardiology and Internal Medicine Units in Europe. 2016 subjects formed the derivation cohort and 4258 the validation cohort. We entered information on cardiac and comorbid candidate prognostic predictors in a multivariable model to predict 1-year outcome. Results: Median age was 69 years, 35.8% were female, 20.6% had a normal ejection fraction, and 65% had at least one comorbidity. During 5861 person-years follow-up, 12.1% of the patients met the study end-point of all-cause death (n = 750) or urgent transplantation (n = 9). The variables that contributed to outcome prediction, listed in decreasing discriminating ability, were: New York Heart Association class III-IV, left ventricular ejection fraction < 20%, no beta-blocker, no renin-angiotensin system inhibitor, severe valve heart disease, atrial fibrillation, diabetes with micro or macroangiopathy, renal dysfunction, anemia, hypertension and older age. The C statistic for 1-year all-cause mortality was 0.87 for the derivation and 0.82 for the validation cohort. Conclusions: The 3C-HF score, based on easy-to-obtain cardiac and comorbid conditions and applicable to the 1-year time span, represents a simple and valuable tool to improve the prognostic stratification of HF patients in daily practice.

Published
2013

108. The PANDA Endcap Disc DIRC

Author

Etzelmuller, E., primary, Ali, A., additional, Belias, A., additional, Dzhygadlo, R., additional, Gerhardt, A., additional, Gotzen, K., additional, Kalicy, G., additional, Krebs, M., additional, Lehmann, D., additional, Nerling, F., additional, Patsyuk, M., additional, Peters, K., additional, Schepers, G., additional, Schmitt, L., additional, Schwarz, C., additional, Schwiening, J., additional, Traxler, M., additional, Bohm, M., additional, Eyrich, W., additional, Lehmann, A., additional, Pfaffinger, M., additional, Uhlig, F., additional, Duren, M., additional, Fohl, K., additional, Hayrapetyan, A., additional, Kreutzfeld, K., additional, Merle, O., additional, Rieke, J., additional, Schmidt, M., additional, Wasem, T., additional, Achenbach, P., additional, Cardinali, M., additional, Hoek, M., additional, Lauth, W., additional, Schlimme, S., additional, Sfienti, C., additional, and Thiel, M., additional

Published
2017
Full Text
View/download PDF

111. 4123Long term effect of transvenous carotid body ablation in the treatment of patients with resistant hypertension

Author

Neuzil, P., primary, Reddy, V., additional, Malek, F., additional, Kmonicek, P., additional, Sievert, H., additional, Zeller, T., additional, Noory, E., additional, Bohm, M., additional, Mahfoud, F., additional, Worthley, S., additional, Montarello, J., additional, Schultz, C., additional, Shetty, S., additional, Hering, D., additional, and Schlaich, M., additional

Published
2017
Full Text
View/download PDF

112. Impact of landscape fragmentation on airflow: wind-tunnel measurements and LES validation

Author

Poette, Christopher, Gardiner, Barry A., Dupont, Sylvain, Brunet, Yves, Harman, Ian N., Bohm, M., Finnigan, John J., Hugues, D., Interactions Sol Plante Atmosphère (UMR ISPA), Institut National de la Recherche Agronomique (INRA)-Ecole Nationale Supérieure des Sciences Agronomiques de Bordeaux-Aquitaine (Bordeaux Sciences Agro), Commonwealth Scientific and Industrial Research Organisation [Canberra] (CSIRO), Australian Meteorological and Oceanographic Society, Partenaires INRAE, and ProdInra, Migration

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

National audience

Published
2015

113. Heart failure with preserved ejection fraction: uncertainties and dilemmas

Author

Ferrari, R., Bohm, M., Cleland, J.G.F., Paulus, W.J.S., Pieske, B., Rapezzi, C., Tavazzi, L., Physiology, ICaR - Heartfailure and pulmonary arterial hypertension, Ferrari, Roberto, Böhm, Michael, Cleland, John G.F., Paulus, Walter J.S., Pieske, Burkert, Rapezzi, Claudio, and Tavazzi, Luigi

Subjects
Prognosi, Medicine (all), Angiotensin Receptor Antagonist, Adrenergic beta-Antagonists, Adrenergic beta-Antagonist, Stroke Volume, Heart failure, Spironolactone, Preserved ejection fraction, Prognosis, Heart failure, Preserved ejection fraction, NO, Angiotensin Receptor Antagonists, Diuretic, Humans, Cardiology and Cardiovascular Medicine, Diuretics, Human
Abstract

Many uncertainties surround the syndrome of heart failure with preserved ejection fraction (HFpEF), which was the topic reviewed in an Expert Meeting at the University of Ferrara. This concluded that the absence of clear diagnostic clinical criteria was the major barrier to progress. There was general agreement that symptoms or signs of heart failure, normal LVEF despite an elevated plasma concentration of natriuretic peptides, and signs of abnormal LV relaxation, LV filling, LV hypertrophy, or left atrial enlargement, or diastolic dysfunction supported the diagnosis. However, HFpEF, like all heart failure syndromes, is heterogeneous in aetiology and pathophysiology, rather than being a single disease. HFpEF may account for about half of all patients with heart failure. The classical risk factors for developing HFpEF include age and co-morbidities, notably hypertension, atrial fibrillation, and the metabolic syndrome. When complicated by increasing congestion requiring hospital admission, the prognosis is poor; 30% or more of patients will die within 1 year (nearly two-thirds die from cardiovascular causes). Patients with chronic stable symptoms have a much better prognosis. Despite many clinical trials, there is no solid evidence that any treatment alters the natural history of HFpEF. Several treatments have shown promising early results and are now being tested in substantial randomized clinical trials. Further basic research is required to better characterize the disease and accelerate progress. Our review highlights the many difficulties encountered in performing randomized clinical trials in HFpEF, often due to difficulties in characterizing HFpEF itself.

Published
2015

114. ESPEN Guidelines on Enteral Nutrition: Cardiology and Pulmonology

Author

Anker, S.D., John, M., Pedersen, P.U., Raguso, C., Cicoira, M., Dardai, E., Laviano, A., Ponikowski, P., Schols, A.M., German Society for Nutritional, Medicine, Becker, H.F., Bohm, M., Brunkhorst, F.M., Vogelmeier, C., Pulmonologie, and RS: NUTRIM School of Nutrition and Translational Research in Metabolism

Subjects
medicine.medical_specialty, medicine.medical_treatment, Cardiology, Critical Care and Intensive Care Medicine, Enteral administration, Cachexia, Pulmonary Disease, Chronic Obstructive, Enteral Nutrition, Weight loss, Internal medicine, Percutaneous endoscopic gastrostomy, medicine, Pulmonary Medicine, Humans, Practice Patterns, Physicians', Intensive care medicine, Heart Failure, COPD, Nutrition and Dietetics, business.industry, Guideline, medicine.disease, Europe, Pulmonology, Parenteral nutrition, medicine.symptom, business
Abstract

These guidelines are intended to give evidence-based recommendations for the use of enteral nutrition (EN) in patients with chronic heart failure (CHF) and chronic obstructive pulmonary disease (COPD). They were developed by an interdisciplinary expert group in accordance with officially accepted standards and are based on all relevant publications since 1985. They have been discussed and accepted in a consensus conference. EN by means of oral nutritional supplements (ONS) or tube feeding (TF) enables nutritional intake to be maintained or increased when normal oral intake is inadequate. No data are yet available concerning the effects of EN on cachexia in CHF patients. However, EN is recommended to stop or reverse weight loss on the basis of physiological plausibility. In COPD patients, EN in combination with exercise and anabolic pharmacotherapy has the potential to improve nutritional status and function. Frequent small amounts of ONS are preferred in order to avoid postprandial dyspnoea and satiety as well as to improve compliance.

Published
2006

115. Simultaneous Measurement of Cardiac Perfusion and Permeability in Vivo with Synchrotron Radiation Imaging

Author

Yu, B, Walenta, A, Bohm, M, Bravin, A, Esteve, F, Erbel, R, Fiedler, S, Kalthoff, O, Mielebacher, J, Mohlenkamp, S, Scheller, B, Schenk, H, Walenta, K, Walenta AH, Bohm M, Bravin A, Esteve F, Erbel R, Fiedler S, Kalthoff O, Mielebacher J, Mohlenkamp S, Scheller B, Schenk HW, Walenta K, Yu, B, Walenta, A, Bohm, M, Bravin, A, Esteve, F, Erbel, R, Fiedler, S, Kalthoff, O, Mielebacher, J, Mohlenkamp, S, Scheller, B, Schenk, H, Walenta, K, Walenta AH, Bohm M, Bravin A, Esteve F, Erbel R, Fiedler S, Kalthoff O, Mielebacher J, Mohlenkamp S, Scheller B, Schenk HW, and Walenta K

Abstract

The high temporal, spatial and contrast resolution of synchrotron radiation imaging (SYRI) allows the measurement of the residual density of an injected contrast medium with high precision and delivers absolute values. This was exploited with measurements on pigs where it could be shown that the identification and characterization of the relevant compartments and their structures allows to record the time dependent contrast medium density in arteries, the myocardium and the veins separately. With an adapted computer based flow model the absolute local determination of the perfusion and for extracellular contrast media (as Gadovise (R)) the permeability through the capillary membrane could be obtained. Model prediction include the option of flow reserve measurement at baseline.

Published
2009

116. Study of doubly strange systems using stored antiprotons

Author

Singh, B., Erni, W., Krusche, B., Steinacher, M., Walford, N., Liu, B., Liu, H., Liu, Z., Shen, X., Wang, C., Zhao, J., Albrecht, M., Erlen, T., Fink, M., Heinsius, F., Held, T., Holtmann, T., Jasper, S., Keshk, I., Koch, H., Kopf, B., Kuhlmann, M., Kuemmel, M., Leiber, S., Mikirtychyants, M., Musiol, P., Mustafa, A., Pelizaeus, M., Pychy, J., Richter, M., Schnier, C., Schroeder, T., Sowa, C., Steinke, M., Triffterer, T., Wiedner, U., Ball, M., Beck, R., Hammann, C., Ketzer, B., Kube, M., Mahlberg, P., Rossbach, M., Schmidt, C., Schmitz, R., Thoma, U., Urban, M., Walther, D., Wendel, C., Wilson, A., Bianconi, A., Bragadireanu, M., Caprini, M., Pantea, D., Patel, B., Czyzycki, W., Domagala, M., Filo, G., Jaworowski, J., Krawczyk, M., Lisowski, E., Lisowski, F., Michalek, M., Poznanski, P., Plazek, J., Korcyl, K., Kozela, A., Kulessa, P., Lebiedowicz, P., Pysz, K., Schaefer, W., Szczurek, A., Fiutowski, T., Idzik, M., Mindur, B., Przyborowski, D., Swientek, K., Biernat, J., Kamys, B., Kistryn, S., Korcyl, G., Krzemien, W., Magiera, A., Moskal, P., Psyzniak, A., Rudy, Z., Salabura, P., Smyrski, J., Strzempek, P., Wronska, A., Augustin, I., Boehm, R., Lehmann, I., Marinescu, D. Nicmorus, Schmitt, L., Varentsov, V., Al-Turany, M., Belias, A., Deppe, H., Dzhygadlo, R., Ehret, A., Flemming, H., Gerhardt, A., Goetzen, K., Gromliuk, A., Gruber, L., Karabowicz, R., Kliemt, R., Krebs, M., Kurillan, U., Lehmann, D., Loechner, S., Luehning, J., Lynen, U., Orth, H., Patsyuk, M., Peters, K., Saito, T., Schepers, G., Schmidt, C. J., Schwarz, C., Schwiening, J., Taeschner, A., Traxler, M., Ugurn, C., Voss, B., Wieczorek, P., Wilms, A., Ziihlsdorfil, M., Abazov, V. M., Alexeev, G., Arefiev, A., Astakhov, V. I., Barabanov, M. Yu., Batyunya, B. V., Davydov, Yu. I., Dodokhov, V. Kh., Efremov, A. A., Fechtchenko, A., Fedunov, A. G., Galoyan, A., Grigoryan, S., Koshurnikov, E. K., Lobanov, V. I., Lobanov, Y. Yu., Makarov, A. F., Malinina, L. V., Malyshev, V. L., Olshevskiy, A., Perevalova, E., Piskun, A. A., Pocheptsov, T., Pontecorvo, G., Rodionov, V., Rogov, Y., Salmin, R., Samartsev, A., Sapozhnikov, M. G., Shabratova, G., Skachkov, N. B., Skachkova, A. N., Strokovsky, E. A., Suleimanov, M., Teshev, R., Tokmenin, V., Uzhinsky, V., Vodopyanov, A., Zaporozhets, S. A., Zhuravlev, N. I., Zorin, A. G., Branford, D., Glazier, D., Watts, D., Bohm, M., Britting, A., Eyrich, W., Lehmann, A., Pfaffinger, M., Uhlig, F., Dobbs, S., Seth, K., Tomaradze, A., Xiao, T., Bettoni, D., Carassiti, V., Ramusino, A. Cotta, Dalpiaz, P., Drago, A., Fioravanti, E., Garzia, I., Savrie, M., Akishina, V., Kisel, I., Kozlov, G., Pugach, M., Zyzak, M., Gianotti, P., Guaraldo, C., Lucherini, V., Bersani, A., Bracco, G., Macri, M., Parodi, R. F., Biguenko, K., Brinkmann, K., Di Pietro, V., Diehl, S., Dormenev, V., Drexler, P., Diiren, M., Etzelmiiller, E., Galuska, M., Gutz, E., Hahn, C., HayrapetYan, A., Kesselkaul, M., Kuhn, W., Kuske, T., Lange, J. S., Liang, Y., Metag, V., Nanova, M., Nazarenko, S., Novotny, R., Quagli, T., Reiter, S., Rieke, J., Rosenbaum, C., Schmidt, M., Schnell, R., Thoring, U., Ullrich, M., Wagner, M. N., Wasem, T., Wohlfarth, B., Zaunick, H., Ireland, D., Rosner, G., Seitz, B., Deepak, P. N., Kulkarni, A., Apostolou, A., Babai, M., Kavatsyuk, M., Lemmens, P., Lindemulder, M., Loehner, H., Messchendorp, J., Schakel, P., Smit, H., Tiemens, M., Van der Weele, J. C., Veenstra, R., Vejdani, S., Dutta, K., Kalita, K., Kumar, A., Roy, A., Sohibach, H., Bai, M., Bianchi, L., Biischer, M., Cao, L., Cebulla, A., Dosdall, R., Gillitzer, A., Goldenbaum, F., Grunwald, D., Herten, A., Hu, Q., Kemmerling, G., Kleines, H., Lehrach, A., Nellen, R., Ohm, H., Orfanitski, S., Prasuhn, D., Prencipe, E., Piitz, J., Ritman, J., Schadmand, S., Sefzick, T., Serdyuk, V., Sterzenbach, G., Stockmanns, T., Wintz, R., Wiistner, P., Xu, H., Zambanini, A., Li, S., Li, Z., Sun, Z., Rigato, V., Isaksson, L., Achenbach, P., Corell, O., Denig, A., Distler, M., Hoek, M., Karavdina, A., Lauth, W., Merkel, H., Miller, U., Pochodzalla, J., Schlimme, S., Sfienti, C., Thiel, M., Ahmadi, H., Ahmed, S., Bleser, S., Capozza, L., Cardinali, M., Dbeyssi, A., Deiseroth, M., Feldbauer, F., Fritsch, M., Frohlich, B., Jasinski, P., Kang, D., Khaneft, D., Klasen, R., Leithoff, H. H., Lin, D., Maas, F., Maldaner, S., Rojo, M. Martinez, Marta, M., Michel, M., Espi, M. C. Mora, Morales, C. Morales, Motzko, C., Nerling, F., Noll, O., Pflager, S., Pitka, A., Pifleiro, D. Rodriguez, Lorente, A. Sanchez, Steinen, M., Valente, R., Weber, T., Zambrana, M., Zimmermann, I., Fedorov, A., Korjik, M., Missevitch, O., Boukharov, A., Malyshev, O., Marishev, I., Balanutsa, P., Balanutsa, V., Chernetsky, V., Demekhin, A., Dolgolenko, A., Fedorets, P., Gerasimov, A., Goryachev, V., Chandratre, V., Datar, V., Dutta, D., Them, V., Kumawat, H., Mohanty, A. K., Parmar, A., Roy, B., Sonika, G., Fritzsch, C., Grieser, S., Hergemoller, A. K., Hetz, B., Hiisken, N., Khoukaz, A., Wessels, J. P., Khosonthongkee, Ank., Kobdaj, C., Limphirat, A., Srisawad, P., Yan, Y., Barnyakov, M., Barnyakov, A. Yu., Beloborodov, K., Blinov, A. E., Blinov, V. E., Bobrovnikov, V. S., Kononov, S., Kravchenko, E. A., Kuyanov, I. A., Martin, K., Onuchin, A. P., Serednyakov, S., Sokolov, A., Tikhonov, Y., Atomssa, E., Kunne, R., Marchand, D., Ramstein, B., Van De Wiele, J., Wang, Y., Boca, G., Costanza, S., Genova, P., Montagne, P., Rotondi, A., Abramov, V., Belikov, N., Bukreeva, S., Davidenko, A., Derevschikov, A., Goncharenko, Y., Grishin, V., Kachanov, V., Kormilitsin, V., Levin, A., Melnik, Y., Minaev, N., Mochalov, V., Morozov, D., Nogach, L., Poslayskiy, S., Ryazantsev, A., Ryzhikov, S., Semenov, P., Shein, I., Uzunian, A., Vasiliev, A., Yakutin, A., Tomasi-Gustafsson, E., Roy, U., Yabsley, B., Belostotski, S., Gavrilov, G., Izotov, A., Manaenkov, S., Miklukho, O., Veretennikov, D., Zhdanov, A., Makonyi, K., Preston, M., Tegner, P., Wolbing, D., Back, T., Cederwall, B., Rai, A. K., Godre, S., Calvo, D., Coli, S., De Remigis, P., Filippi, A., Giraudo, G., Lusso, S., Mazza, G., Mignone, M., Rivetti, A., Wheadon, R., Balestra, F., Iazzi, F., Introzzi, R., Lavagno, A., Olave, J., Amoroso, A., Bussa, M. P., Busso, L., De Mori, F., Destefanis, M., Fava, L., Ferrero, L., Greco, M., Hu, J., Lavezzi, L., Maggiore, M., Maniscalco, G., Marcello, S., Sosio, S., Spataro, S., Birsa, R., Bradamante, F., Bressan, A., Martin, A., Calén, Hans, Andersson, Walter Ikegami, Johansson, Tord, Kupsc, Andrzej, Marciniewski, Pawel, Papenbrock, Michael, Pettersson, Joachim, Schönning, Karin, Wolke, Magnus, Gålnander, Björn, Diaz, J., Chackara, V. Pothodi, Chlopik, A., Kesik, G., Melnychuk, D., Slowinski, B., Trzcinski, A., Wojciechowski, M., Wronka, S., Zwieglinski, B., Buehler, P., Marton, J., Steinschaden, D., Suzuki, K., Widmann, E., Zmeskal, J., Gerin, Juergen, Kojouharov, Ivan, Kojouharova, Jasmina, Singh, B., Erni, W., Krusche, B., Steinacher, M., Walford, N., Liu, B., Liu, H., Liu, Z., Shen, X., Wang, C., Zhao, J., Albrecht, M., Erlen, T., Fink, M., Heinsius, F., Held, T., Holtmann, T., Jasper, S., Keshk, I., Koch, H., Kopf, B., Kuhlmann, M., Kuemmel, M., Leiber, S., Mikirtychyants, M., Musiol, P., Mustafa, A., Pelizaeus, M., Pychy, J., Richter, M., Schnier, C., Schroeder, T., Sowa, C., Steinke, M., Triffterer, T., Wiedner, U., Ball, M., Beck, R., Hammann, C., Ketzer, B., Kube, M., Mahlberg, P., Rossbach, M., Schmidt, C., Schmitz, R., Thoma, U., Urban, M., Walther, D., Wendel, C., Wilson, A., Bianconi, A., Bragadireanu, M., Caprini, M., Pantea, D., Patel, B., Czyzycki, W., Domagala, M., Filo, G., Jaworowski, J., Krawczyk, M., Lisowski, E., Lisowski, F., Michalek, M., Poznanski, P., Plazek, J., Korcyl, K., Kozela, A., Kulessa, P., Lebiedowicz, P., Pysz, K., Schaefer, W., Szczurek, A., Fiutowski, T., Idzik, M., Mindur, B., Przyborowski, D., Swientek, K., Biernat, J., Kamys, B., Kistryn, S., Korcyl, G., Krzemien, W., Magiera, A., Moskal, P., Psyzniak, A., Rudy, Z., Salabura, P., Smyrski, J., Strzempek, P., Wronska, A., Augustin, I., Boehm, R., Lehmann, I., Marinescu, D. Nicmorus, Schmitt, L., Varentsov, V., Al-Turany, M., Belias, A., Deppe, H., Dzhygadlo, R., Ehret, A., Flemming, H., Gerhardt, A., Goetzen, K., Gromliuk, A., Gruber, L., Karabowicz, R., Kliemt, R., Krebs, M., Kurillan, U., Lehmann, D., Loechner, S., Luehning, J., Lynen, U., Orth, H., Patsyuk, M., Peters, K., Saito, T., Schepers, G., Schmidt, C. J., Schwarz, C., Schwiening, J., Taeschner, A., Traxler, M., Ugurn, C., Voss, B., Wieczorek, P., Wilms, A., Ziihlsdorfil, M., Abazov, V. M., Alexeev, G., Arefiev, A., Astakhov, V. I., Barabanov, M. Yu., Batyunya, B. V., Davydov, Yu. I., Dodokhov, V. Kh., Efremov, A. A., Fechtchenko, A., Fedunov, A. G., Galoyan, A., Grigoryan, S., Koshurnikov, E. K., Lobanov, V. I., Lobanov, Y. Yu., Makarov, A. F., Malinina, L. V., Malyshev, V. L., Olshevskiy, A., Perevalova, E., Piskun, A. A., Pocheptsov, T., Pontecorvo, G., Rodionov, V., Rogov, Y., Salmin, R., Samartsev, A., Sapozhnikov, M. G., Shabratova, G., Skachkov, N. B., Skachkova, A. N., Strokovsky, E. A., Suleimanov, M., Teshev, R., Tokmenin, V., Uzhinsky, V., Vodopyanov, A., Zaporozhets, S. A., Zhuravlev, N. I., Zorin, A. G., Branford, D., Glazier, D., Watts, D., Bohm, M., Britting, A., Eyrich, W., Lehmann, A., Pfaffinger, M., Uhlig, F., Dobbs, S., Seth, K., Tomaradze, A., Xiao, T., Bettoni, D., Carassiti, V., Ramusino, A. Cotta, Dalpiaz, P., Drago, A., Fioravanti, E., Garzia, I., Savrie, M., Akishina, V., Kisel, I., Kozlov, G., Pugach, M., Zyzak, M., Gianotti, P., Guaraldo, C., Lucherini, V., Bersani, A., Bracco, G., Macri, M., Parodi, R. F., Biguenko, K., Brinkmann, K., Di Pietro, V., Diehl, S., Dormenev, V., Drexler, P., Diiren, M., Etzelmiiller, E., Galuska, M., Gutz, E., Hahn, C., HayrapetYan, A., Kesselkaul, M., Kuhn, W., Kuske, T., Lange, J. S., Liang, Y., Metag, V., Nanova, M., Nazarenko, S., Novotny, R., Quagli, T., Reiter, S., Rieke, J., Rosenbaum, C., Schmidt, M., Schnell, R., Thoring, U., Ullrich, M., Wagner, M. N., Wasem, T., Wohlfarth, B., Zaunick, H., Ireland, D., Rosner, G., Seitz, B., Deepak, P. N., Kulkarni, A., Apostolou, A., Babai, M., Kavatsyuk, M., Lemmens, P., Lindemulder, M., Loehner, H., Messchendorp, J., Schakel, P., Smit, H., Tiemens, M., Van der Weele, J. C., Veenstra, R., Vejdani, S., Dutta, K., Kalita, K., Kumar, A., Roy, A., Sohibach, H., Bai, M., Bianchi, L., Biischer, M., Cao, L., Cebulla, A., Dosdall, R., Gillitzer, A., Goldenbaum, F., Grunwald, D., Herten, A., Hu, Q., Kemmerling, G., Kleines, H., Lehrach, A., Nellen, R., Ohm, H., Orfanitski, S., Prasuhn, D., Prencipe, E., Piitz, J., Ritman, J., Schadmand, S., Sefzick, T., Serdyuk, V., Sterzenbach, G., Stockmanns, T., Wintz, R., Wiistner, P., Xu, H., Zambanini, A., Li, S., Li, Z., Sun, Z., Rigato, V., Isaksson, L., Achenbach, P., Corell, O., Denig, A., Distler, M., Hoek, M., Karavdina, A., Lauth, W., Merkel, H., Miller, U., Pochodzalla, J., Schlimme, S., Sfienti, C., Thiel, M., Ahmadi, H., Ahmed, S., Bleser, S., Capozza, L., Cardinali, M., Dbeyssi, A., Deiseroth, M., Feldbauer, F., Fritsch, M., Frohlich, B., Jasinski, P., Kang, D., Khaneft, D., Klasen, R., Leithoff, H. H., Lin, D., Maas, F., Maldaner, S., Rojo, M. Martinez, Marta, M., Michel, M., Espi, M. C. Mora, Morales, C. Morales, Motzko, C., Nerling, F., Noll, O., Pflager, S., Pitka, A., Pifleiro, D. Rodriguez, Lorente, A. Sanchez, Steinen, M., Valente, R., Weber, T., Zambrana, M., Zimmermann, I., Fedorov, A., Korjik, M., Missevitch, O., Boukharov, A., Malyshev, O., Marishev, I., Balanutsa, P., Balanutsa, V., Chernetsky, V., Demekhin, A., Dolgolenko, A., Fedorets, P., Gerasimov, A., Goryachev, V., Chandratre, V., Datar, V., Dutta, D., Them, V., Kumawat, H., Mohanty, A. K., Parmar, A., Roy, B., Sonika, G., Fritzsch, C., Grieser, S., Hergemoller, A. K., Hetz, B., Hiisken, N., Khoukaz, A., Wessels, J. P., Khosonthongkee, Ank., Kobdaj, C., Limphirat, A., Srisawad, P., Yan, Y., Barnyakov, M., Barnyakov, A. Yu., Beloborodov, K., Blinov, A. E., Blinov, V. E., Bobrovnikov, V. S., Kononov, S., Kravchenko, E. A., Kuyanov, I. A., Martin, K., Onuchin, A. P., Serednyakov, S., Sokolov, A., Tikhonov, Y., Atomssa, E., Kunne, R., Marchand, D., Ramstein, B., Van De Wiele, J., Wang, Y., Boca, G., Costanza, S., Genova, P., Montagne, P., Rotondi, A., Abramov, V., Belikov, N., Bukreeva, S., Davidenko, A., Derevschikov, A., Goncharenko, Y., Grishin, V., Kachanov, V., Kormilitsin, V., Levin, A., Melnik, Y., Minaev, N., Mochalov, V., Morozov, D., Nogach, L., Poslayskiy, S., Ryazantsev, A., Ryzhikov, S., Semenov, P., Shein, I., Uzunian, A., Vasiliev, A., Yakutin, A., Tomasi-Gustafsson, E., Roy, U., Yabsley, B., Belostotski, S., Gavrilov, G., Izotov, A., Manaenkov, S., Miklukho, O., Veretennikov, D., Zhdanov, A., Makonyi, K., Preston, M., Tegner, P., Wolbing, D., Back, T., Cederwall, B., Rai, A. K., Godre, S., Calvo, D., Coli, S., De Remigis, P., Filippi, A., Giraudo, G., Lusso, S., Mazza, G., Mignone, M., Rivetti, A., Wheadon, R., Balestra, F., Iazzi, F., Introzzi, R., Lavagno, A., Olave, J., Amoroso, A., Bussa, M. P., Busso, L., De Mori, F., Destefanis, M., Fava, L., Ferrero, L., Greco, M., Hu, J., Lavezzi, L., Maggiore, M., Maniscalco, G., Marcello, S., Sosio, S., Spataro, S., Birsa, R., Bradamante, F., Bressan, A., Martin, A., Calén, Hans, Andersson, Walter Ikegami, Johansson, Tord, Kupsc, Andrzej, Marciniewski, Pawel, Papenbrock, Michael, Pettersson, Joachim, Schönning, Karin, Wolke, Magnus, Gålnander, Björn, Diaz, J., Chackara, V. Pothodi, Chlopik, A., Kesik, G., Melnychuk, D., Slowinski, B., Trzcinski, A., Wojciechowski, M., Wronka, S., Zwieglinski, B., Buehler, P., Marton, J., Steinschaden, D., Suzuki, K., Widmann, E., Zmeskal, J., Gerin, Juergen, Kojouharov, Ivan, and Kojouharova, Jasmina

Abstract

Bound nuclear systems with two units of strangeness are still poorly known despite their importance for many strong interaction phenomena. Stored antiprotons beams in the GeV range represent an unparalleled factory for various hyperon-antihyperon pairs. Their outstanding large production probability in antiproton collisions will open the floodgates for a series of new studies of systems which contain two or even more units of strangeness at the PANDA experiment at FAIR. For the first time, high resolution gamma-spectroscopy of doubly strange Lambda Lambda-hypernuclei will be performed, thus complementing measurements of ground state decays of Lambda Lambda-hypernuclei at J-PARC or possible decays of particle unstable hypernuclei in heavy ion reactions. High resolution spectroscopy of multistrange Xi(-) -atoms will be feasible and even the production of Omega(-) -atoms will be within reach. The latter might open the door to the vertical bar S vertical bar = 3 world in strangeness nuclear physics, by the study of the hadronic Omega(-) -nucleus interaction. For the first time it will be possible to study the behavior of Xi(+) in nuclear systems under well controlled conditions.

Published
2016
Full Text
View/download PDF

117. Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants

Author

Jin, Y., Andersen, G., Yorgov, D., Ferrara, T.M., Ben, S., Brownson, K.M., Holland, P.J., Birlea, S.A., Siebert, J., Hartmann, A., Lienert, A., van Geel, N., Lambert, J., Luiten, R.M., Wolkerstorfer, A., Wietze van der Veen, J.P., Bennett, D.C., Taïeb, A., Ezzedine, K., Kemp, E.H., Gawkrodger, D.J., Weetman, A.P., Kõks, S., Prans, E., Kingo, K., Karelson, M., Wallace, M.R., McCormack, W.T., Overbeck, A., Moretti, S., Colucci, R., Picardo, M., Silverberg, N.B., Olsson, M., Valle, Y., Korobko, I., Bohm, M., Lim, H.W., Hamzavi, I., Zhou, L., Mi, Q-S, Fain, P.R., Santorico, S.A., Spritz, R.A., Jin, Y., Andersen, G., Yorgov, D., Ferrara, T.M., Ben, S., Brownson, K.M., Holland, P.J., Birlea, S.A., Siebert, J., Hartmann, A., Lienert, A., van Geel, N., Lambert, J., Luiten, R.M., Wolkerstorfer, A., Wietze van der Veen, J.P., Bennett, D.C., Taïeb, A., Ezzedine, K., Kemp, E.H., Gawkrodger, D.J., Weetman, A.P., Kõks, S., Prans, E., Kingo, K., Karelson, M., Wallace, M.R., McCormack, W.T., Overbeck, A., Moretti, S., Colucci, R., Picardo, M., Silverberg, N.B., Olsson, M., Valle, Y., Korobko, I., Bohm, M., Lim, H.W., Hamzavi, I., Zhou, L., Mi, Q-S, Fain, P.R., Santorico, S.A., and Spritz, R.A.

Abstract

Vitiligo is an autoimmune disease in which depigmented skin results from the destruction of melanocytes1, with epidemiological association with other autoimmune diseases2. In previous linkage and genome-wide association studies (GWAS1 and GWAS2), we identified 27 vitiligo susceptibility loci in patients of European ancestry. We carried out a third GWAS (GWAS3) in European-ancestry subjects, with augmented GWAS1 and GWAS2 controls, genome-wide imputation, and meta-analysis of all three GWAS, followed by an independent replication. The combined analyses, with 4,680 cases and 39,586 controls, identified 23 new significantly associated loci and 7 suggestive loci. Most encode immune and apoptotic regulators, with some also associated with other autoimmune diseases, as well as several melanocyte regulators. Bioinformatic analyses indicate a predominance of causal regulatory variation, some of which corresponds to expression quantitative trait loci (eQTLs) at these loci. Together, the identified genes provide a framework for the genetic architecture and pathobiology of vitiligo, highlight relationships with other autoimmune diseases and melanoma, and offer potential targets for treatment.

Published
2016

118. RHAPSODY - Internet-based support for caregivers of people with young onset dementia: program design and methods of a pilot study

Author

Kurz, A., Bakker, C., Bohm, M., Diehl, J., Dubois, B., Ferreira, C., Gage, H., Graff, C., Hergueta, T., Jansen, S., Jones, B., Komar, A., Mendonca, A. de, Metcalfe, A., Milecka, K., Millenaar, J., Wallin, A., Oyebode, J., Schneider-Schelte, H., Saxl, S., Vugt, M. De, Kurz, A., Bakker, C., Bohm, M., Diehl, J., Dubois, B., Ferreira, C., Gage, H., Graff, C., Hergueta, T., Jansen, S., Jones, B., Komar, A., Mendonca, A. de, Metcalfe, A., Milecka, K., Millenaar, J., Wallin, A., Oyebode, J., Schneider-Schelte, H., Saxl, S., and Vugt, M. De

Abstract

Item does not contain fulltext, BACKGROUND: Young Onset Dementia (YOD), defined by first symptoms of cognitive or behavioral decline occurring before the age of 65 years, is relatively rare compared to dementia of later onset, but it is associated with diagnostic difficulty and heavy burden on affected individuals and their informal carers. Existing health and social care structures rarely meet the needs of YOD patients. Internet-based interventions are a novel format of delivering health-related education, counseling, and support to this vulnerable yet underserved group. METHODS: The RHAPSODY (Research to Assess Policies and Strategies for Dementia in the Young) project is a European initiative to improve care for people with YOD by providing an internet-based information and skill-building program for family carers. The e-learning program focuses on managing problem behaviors, dealing with role change, obtaining support, and looking after oneself. It will be evaluated in a pilot study in three countries using a randomized unblinded design with a wait-list control group. Participants will be informal carers of people with dementia in Alzheimer's disease or behavioral-variant Frontotemporal degeneration with an onset before the age of 65 years. The primary outcome will be caregiving self-efficacy after 6 weeks of program use. As secondary outcomes, caregivers' stress and burden, carer health-related quality of life, caring-related knowledge, patient problem behaviors, and user satisfaction will be assessed. Program utilization will be monitored and a health-economic evaluation will also be performed. CONCLUSIONS: The RHAPSODY project will add to the evidence on the potential and limitations of a conveniently accessible, user-friendly, and comprehensive internet-based intervention as an alternative for traditional forms of counseling and support in healthcare, aiming to optimize care and support for people with YOD and their informal caregivers.

Published
2016

119. Renal denervation in hypertensive patients not on blood pressure lowering drugs

Author

De Jager, R L, Sanders, M F, Bots, ML, Lobo, M D, Ewen, S, Beeftink, M M A, Bohm, M, Daemen, Joost, Dorr, O, Hering, D, Mahfoud, F, Nef, H, Ott, C, Saxena, M, Schmieder, RE, Schlaich, M P, Spiering, W, Tonino, PAL, Verloop, W L, Vink, EE, Vonken, EJ, Voskuil, M, Worthley, S G, Blankestijn, PJ (Peter), De Jager, R L, Sanders, M F, Bots, ML, Lobo, M D, Ewen, S, Beeftink, M M A, Bohm, M, Daemen, Joost, Dorr, O, Hering, D, Mahfoud, F, Nef, H, Ott, C, Saxena, M, Schmieder, RE, Schlaich, M P, Spiering, W, Tonino, PAL, Verloop, W L, Vink, EE, Vonken, EJ, Voskuil, M, Worthley, S G, and Blankestijn, PJ (Peter)

Published
2016

120. Power quality issues related to new means of distributed generation and loads

Author

KLING W. L, ORTHS A, CUK V, COBBEN J. F. G, TIMENS R. B, VERHELST B, DEBRUYNE C, DESMET J, VANDEVELDE L, RIBEIRO P. F, LEITAO J. J. A. L, DA SILVA LIRA M. M, MACEDO J. R, GRANDI A. L. Z, BROWNE N, KONIG S, JAGER J, PREIS D, BOHM M, ROMERO GORDON J. M, MEYER J, SCHEGNER P, HESKES P. J. M, MYRZIK J. M. A., TESTA, Alfredo, LANGELLA, Roberto, Kling, W. L., Orths, A, Cuk, V, Cobben, J. F. G., Timens, R. B., Verhelst, B, Debruyne, C, Desmet, J, Vandevelde, L, Ribeiro, P. F., Leitao, J. J. A. L., DA SILVA LIRA, M. M., Macedo, J. R., Grandi, A. L. Z., Testa, Alfredo, Langella, Roberto, Browne, N, Konig, S, Jager, J, Preis, D, Bohm, M, ROMERO GORDON, J. M., Meyer, J, Schegner, P, Heskes, P. J. M., and Myrzik, J. M. A.

Published
2011

121. The influence of forest fragmentation on wind flow and the risk of wind damage

Author

Poette, Christopher, Gardiner, Barry A., Bohm, M., Dupont, Sylvain, Brunet, Yves, Interactions Sol Plante Atmosphère (UMR ISPA), Institut National de la Recherche Agronomique (INRA)-Ecole Nationale Supérieure des Sciences Agronomiques de Bordeaux-Aquitaine (Bordeaux Sciences Agro), Australian Meteorological and Oceanographic Society, Partenaires INRAE, International Union of Forest Research Organisations (IUFRO). AUT., and ProdInra, Migration

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2014

125. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design

Author

Mahfoud, F., Bohm, M., Azizi, M., Pathak, A., Durand Zaleski, I., Ewen, S., Tsioufis, K., Andersson, B., Blankestijn, P.J., Burnier, M., Chatellier, G., Gafoor, S., Grassi, G., Joner, M., Kjeldsen, S.E., Luscher, T.F., Lobo, M.D., Lotan, C., Parati, G., Redon, J., Ruilope, L., Sudano, I., Ukena, C., Leeuwen, E. van, Volpe, M., Windecker, S., Witkowski, A., Wijns, W., Zeller, T., Schmieder, R.E., Mahfoud, F., Bohm, M., Azizi, M., Pathak, A., Durand Zaleski, I., Ewen, S., Tsioufis, K., Andersson, B., Blankestijn, P.J., Burnier, M., Chatellier, G., Gafoor, S., Grassi, G., Joner, M., Kjeldsen, S.E., Luscher, T.F., Lobo, M.D., Lotan, C., Parati, G., Redon, J., Ruilope, L., Sudano, I., Ukena, C., Leeuwen, E. van, Volpe, M., Windecker, S., Witkowski, A., Wijns, W., Zeller, T., and Schmieder, R.E.

Abstract

Item does not contain fulltext

Published
2015

126. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure

Author

Packer, M., McMurray, J.J., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R., Rouleau, J.L., Shi, V.C., Solomon, S.D., Swedberg, K., Zile, M., Andersen, K., Arango, J.L., Arnold, J.M., Belohlavek, J., Bohm, M., Boytsov, S., Burgess, L.J., Cabrera, W., Calvo, C., Chen, C.H., Dukat, A., Duarte, Y.C., Erglis, A., Fu, M., Gomez, E., Gonzalez-Medina, A., Hagege, A.A., Huang, J., Katova, T., Kiatchoosakun, S., Kim, K.S., Kozan, O., Llamas, E.B., Martinez, F., Merkely, B., Mendoza, I., Mosterd, A., Negrusz-Kawecka, M., Peuhkurinen, K., Ramires, F.J., Refsgaard, J., Rosenthal, A., Senni, M., Sibulo, A.S., Jr., Silva-Cardoso, J., Squire, I.B., Starling, R.C., Teerlink, J.R., Vanhaecke, J., Vinereanu, D., Wong, R.C., Bellersen, L., et al., Packer, M., McMurray, J.J., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R., Rouleau, J.L., Shi, V.C., Solomon, S.D., Swedberg, K., Zile, M., Andersen, K., Arango, J.L., Arnold, J.M., Belohlavek, J., Bohm, M., Boytsov, S., Burgess, L.J., Cabrera, W., Calvo, C., Chen, C.H., Dukat, A., Duarte, Y.C., Erglis, A., Fu, M., Gomez, E., Gonzalez-Medina, A., Hagege, A.A., Huang, J., Katova, T., Kiatchoosakun, S., Kim, K.S., Kozan, O., Llamas, E.B., Martinez, F., Merkely, B., Mendoza, I., Mosterd, A., Negrusz-Kawecka, M., Peuhkurinen, K., Ramires, F.J., Refsgaard, J., Rosenthal, A., Senni, M., Sibulo, A.S., Jr., Silva-Cardoso, J., Squire, I.B., Starling, R.C., Teerlink, J.R., Vanhaecke, J., Vinereanu, D., Wong, R.C., Bellersen, L., and et al.

Abstract

Item does not contain fulltext, BACKGROUND: Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients. METHODS AND RESULTS: We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction in a double-blind trial. The analyses focused on prespecified measures of nonfatal clinical deterioration. In comparison with the enalapril group, fewer LCZ696-treated patients required intensification of medical treatment for heart failure (520 versus 604; hazard ratio, 0.84; 95% confidence interval, 0.74-0.94; P=0.003) or an emergency department visit for worsening heart failure (hazard ratio, 0.66; 95% confidence interval, 0.52-0.85; P=0.001). The patients in the LCZ696 group had 23% fewer hospitalizations for worsening heart failure (851 versus 1079; P<0.001) and were less likely to require intensive care (768 versus 879; 18% rate reduction, P=0.005), to receive intravenous positive inotropic agents (31% risk reduction, P<0.001), and to have implantation of a heart failure device or cardiac transplantation (22% risk reduction, P=0.07). The reduction in heart failure hospitalization with LCZ696 was evident within the first 30 days after randomization. Worsening of symptom scores in surviving patients was consistently more common in the enalapril group. LCZ696 led to an early and sustained reduction in biomarkers of myocardial wall stress and injury (N-terminal pro-B-type natriuretic peptide and troponin) versus enalapril. CONCLUSIONS: Angiotensin-neprilysin inhibition prevents the clinical progression of surviving patients with heart failure more effectively than angiotensin-converting enzyme inhibition. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifi

Published
2015

127. Multiple drivers of decline in the global status of freshwater crayfish (Decapoda: Astacidea)

Author

Richman, N.I., Bohm, M., Adams, S.B., Alvarez, F., Bergey, E.A., Bunn, J.J.S., Burnham, Q., Cordeiro, J., Coughran, J., Crandall, K.A., Dawkins, K.L., DiStefano, R.J., Doran, N.E., Edsman, L., Eversole, A.G., Fureder, L., Furse, J.M., Gherardi, F., Hamr, P., Holdich, D.M., Horwitz, P., Johnston, K., Jones, C.M., Jones, J.P.G., Jones, R.L., Jones, T.G., Kawai, T., Lawler, S., Lopez-Mejia, M., Miller, R.M., Pedraza-Lara, C., Reynolds, J.D., Richardson, A.M.M., Schultz, M.B., Schuster, G.A., Sibley, P.J., Souty-Grosset, C., Taylor, C.A., Thoma, R.F., Walls, J., Walsh, T.S., Collen, B., Richman, N.I., Bohm, M., Adams, S.B., Alvarez, F., Bergey, E.A., Bunn, J.J.S., Burnham, Q., Cordeiro, J., Coughran, J., Crandall, K.A., Dawkins, K.L., DiStefano, R.J., Doran, N.E., Edsman, L., Eversole, A.G., Fureder, L., Furse, J.M., Gherardi, F., Hamr, P., Holdich, D.M., Horwitz, P., Johnston, K., Jones, C.M., Jones, J.P.G., Jones, R.L., Jones, T.G., Kawai, T., Lawler, S., Lopez-Mejia, M., Miller, R.M., Pedraza-Lara, C., Reynolds, J.D., Richardson, A.M.M., Schultz, M.B., Schuster, G.A., Sibley, P.J., Souty-Grosset, C., Taylor, C.A., Thoma, R.F., Walls, J., Walsh, T.S., and Collen, B.

Abstract

Rates of biodiversity loss are higher in freshwater ecosystems than in most terrestrial or marine ecosystems, making freshwater conservation a priority. However, prioritization methods are impeded by insufficient knowledge on the distribution and conservation status of freshwater taxa, particularly invertebrates. We evaluated the extinction risk of the world’s 590 freshwater crayfish species using the IUCN Categories and Criteria and found 32% of all species are threatened with extinction. The level of extinction risk differed between families, with proportionally more threatened species in the Parastacidae and Astacidae than in the Cambaridae. Four described species were Extinct and 21% were assessed as Data Deficient. There was geographical variation in the dominant threats affecting the main centres of crayfish diversity. The majority of threatened US and Mexican species face threats associated with urban development, pollution, damming and water management. Conversely, the majority of Australian threatened species are affected by climate change, harvesting, agriculture and invasive species. Only a small proportion of crayfish are found within the boundaries of protected areas, suggesting that alternative means of long-term protection will be required. Our study highlights many of the significant challenges yet to come for freshwater biodiversity unless conservation planning shifts from a reactive to proactive approach.

Published
2015

128. Delineating the role of multiple intraarticular corticosteroid injections in the management of juvenile idiopathic arthritis in the biologic era

Author

Papadopoulou, C, Kostik, M, Gonzalez Fernandez MI, Bohm, M, Nieto Gonzalez JC, Pistorio, A, Lanni, Stefano, Consolaro, Alessandro, Martini, Alberto, and Ravelli, Angelo

Subjects
Male, Biological Products, Chi-Square Distribution, Synovitis, Time Factors, Remission Induction, Infant, Kaplan-Meier Estimate, Methylprednisolone, Triamcinolone Acetonide, Arthritis, Juvenile, Disease-Free Survival, Injections, Intra-Articular, Methylprednisolone Acetate, Treatment Outcome, Adrenal Cortex Hormones, Recurrence, Risk Factors, Child, Preschool, Humans, Female, Child, Proportional Hazards Models, Retrospective Studies
Abstract

To investigate the outcome and predicting factors of multiple intraarticular corticosteroid (IAC) injections in children with juvenile idiopathic arthritis (JIA).The clinical charts of patients who received their first IAC injection in ≥3 joints between January 2002 and December 2011 were reviewed. The corticosteroid used was triamcinolone hexacetonide for large joints and methylprednisolone acetate for small or difficult to access joints. In each patient, the followup period after IAC injection was censored in case of synovitis flare or at the last visit with continued remission. Predictors included sex, age at disease onset, JIA category, antinuclear antibody (ANA) status, age and disease duration, disease course, general anesthesia, number and type of injected joints, acute-phase reactants, and concomitant systemic medications.A total of 220 patients who had 1,096 joints injected were included. Following IAC therapy, 66.4% of patients had synovitis flare after a median of 0.5 years, whereas 33.6% of patients had sustained remission after a median of 0.9 years. The cumulative probability of survival without synovitis flare was 50.0%, 31.5%, and 19.5% at 1, 2, and 3 years, respectively. On Cox regression analysis, positive C-reactive protein value, negative ANA, lack of concomitant methotrexate administration, and a polyarticular (versus an oligoarticular) disease course were the strongest predictors for synovitis flare.Multiple IAC injection therapy induced sustained remission of joint synovitis in a substantial proportion of patients. A controlled trial comparing multiple IAC injection therapy and methotrexate versus methotrexate and a tumor necrosis factor antagonist is worthy of consideration.

Published
2012

129. Early drop in systolic blood pressure and worsening renal function in acute heart failure: Renal results of Pre-RELAX-AHF

Author

Voors, A.A. Davison, B.A. Felker, G.M. Ponikowski, P. Unemori, E. Cotter, G. Teerlink, J.R. Greenberg, B.H. Filippatos, G. Teichman, S.L. Metra, M. Teichman, S.L. Massie, B.M. Goldstein, S. Bohm, M. Francis, G. Davis, C.E. Boldueva, S. Moiseev, V. Shogenov, Z. Ruda, M. Vishnevsky, A. Boyarkin, M. Simanenkov, V. Tereschenko, S. Shwartz, Y. Orlikova, O. Arkhipov, M. Libov, I. Sardinov, R. Suvorov, A. Marmor, A. Katz, A. Zimlichman, R. Omary, M. Hershkoviz, R. Goland, S. Keren, A. Aronson, D. Grzybowski, J. Musial, W. Apró, D. Lupkovics, G. Stamate, C. Salajan, A. Matei, A. Levy, P. Pang, P. Collins, S. Gupta, D. Van Mieghem, W. Muyldermans, L. Vervoort, G.

Abstract

Aims We aimed to determine the relation between baseline systolic blood pressure (SBP), change in SBP, and worsening renal function (WRF) in acute heart failure (AHF) patients enrolled in the Pre-RELAX-AHF trial. Methods and resultsThe Pre-RELAX-AHF study enrolled 234 patients within 16 h of admission (median 7 h) for AHF and randomized them to relaxin given intravenous (i.v.) for 48 h or placebo. Blood pressure was measured at baseline, at 3, 6, 9, 12, 24, 36, and 48 h and at 3, 4, and 5 days after enrolment. Worsening renal function was defined as a serum creatinine increase of

Published
2011

134. Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases

Author

Cobb, J., Cule, E., Moncrieffe, H. (Halima), Hinks, A., Ursu, S. (Simona), Patrick, F., Kassoumeri, L., Flynn, E., Bulatovic, M. (Maja), Wulffraat, N.M. (Nico), Zelst, B.D. (Bertrand) van, Jonge, R. (Robert) de, Bohm, M. (Michael), Dolezalova, P. (Pavla), Hirani, S., Newman, S., Whitworth, P., Southwood, T.R., Iorio, M. (Maria) de, Wedderburn, L.R. (Lucy), Thomson, W. (Wendy), Cobb, J., Cule, E., Moncrieffe, H. (Halima), Hinks, A., Ursu, S. (Simona), Patrick, F., Kassoumeri, L., Flynn, E., Bulatovic, M. (Maja), Wulffraat, N.M. (Nico), Zelst, B.D. (Bertrand) van, Jonge, R. (Robert) de, Bohm, M. (Michael), Dolezalova, P. (Pavla), Hirani, S., Newman, S., Whitworth, P., Southwood, T.R., Iorio, M. (Maria) de, Wedderburn, L.R. (Lucy), and Thomson, W. (Wendy)

Abstract

Clinical response to methotrexate (MTX) treatment for children with juvenile idiopathic arthritis (JIA) displays considerable heterogeneity. Currently, there are no reliable predictors to identify non-responders: earlier identification could lead to a targeted treatment. We genotyped 759 JIA cases from the UK, the Netherlands and Czech Republic. Clinical variables were measured at baseline and 6 months after start of the treatment. In Phase I analysis, samples were analysed for the association with MTX response using ordinal regression of ACR-pedi categories and linear regression of change in clinical variables, and identified 31 genetic regions (P<0.001). Phase II analysis increased SNP density in the most strongly associated regions, identifying 14 regions (P<1 × 10 -5): three contain genes of particular biological interest (ZMIZ1, TGIF1 and CFTR). These data suggest a role for novel pathways in MTX response and further investigations within associated regions will help to reach our goal of predicting response to MTX in JIA.

Published
2014
Full Text
View/download PDF

138. Are the arts the language of the brain?

Author

Ossing, F., Bohm, M., Aksel, O., Riiser, A., Beyer, S., and Staff Scientific Executive Board, GFZ Publication Database, Deutsches GeoForschungsZentrum

Subjects
550 - Earth sciences
Published
2008

140. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008

Author

Dickstein, K, Cohen-Solal, A, Filippatos, G, Mcmurray, Jj, Ponikowski, P, Poole-Wilson, Pa, Stromberg, A, van Veldhuisen DJ, Atar, D, Hoes, Aw, Keren, A, Mebazaa, A, Nieminen, M, Priori, Sg, Swedberg, K, Vahanian, A, Camm, J, De Caterina, R, Dean, V, Funck-Brentano, C, Hellemans, I, Kristensen, Sd, Mcgregor, K, Sechtem, U, Silber, S, Tendera, M, Widimsky, P, Zamorano, Jl, Auricchio, A, Bax, J, Bohm, M, Corra, U, Della Bella, P, Elliott, Pm, Follath, F, Gheorghiade, M, Hasin, Y, Hernborg, A, Jaarsma, T, Komajda, M, Kornowski, R, Piepoli, M, Prendergast, B, Tavazzi, L, Vachiery, Jl, Verheugt, Fw, and Zannad, F

Published
2008

141. Seismic structure of Java

Author

Wagner, D., Rabbel, W., Lühr, B., Wassermann, J., Walter, T., Kopp, H., Koulakov, I., Wittwer, A., Bohm, M., Asch, G., and MERAMEX scientists

Subjects
550 - Earth sciences
Published
2008

145. What are subcutaneous adipocytes really good for?

Author

Klein J., Permana P.A., Owecki M., Chaldakov G.N., Bohm M., Hausman G., Lapiere C.M., Atanassova P., Sowinski J., Fasshauer M., Hausman D.B., Maquoi E., Tonchev A.B., Peneva V.N., Vlachanov K.P., Fiore M., and Aloe L.

Abstract

Our acute awareness of the cosmetic, psychosocial and sexual importance of subcutaneous adipose tissue contrasts dramatically with how poorly we have understood the biology of this massive, enigmatic, often ignored and much-abused skin compartment. Therefore, it is timely to recall the exciting, steadily growing, yet underappreciated body of evidence that subcutaneous adipocytes are so much more than just 'fat guys', hanging around passively to conspire, at most, against your desperate attempts to maintain ideal weight. Although the subcutis, quantitatively, tends to represent the dominant architectural component of human skin, conventional wisdom confines its biological key functions to those of energy storage, physical buffer, thermoregulation and thermoinsulation. However, already the distribution of human superficial adipose tissue, by itself, questions how justified the popular belief is that 'skin fat' (which actually may be more diverse than often assumed) serves primarily thermoinsulatory purposes. And although the metabolic complications of obesity are well appreciated, our understanding of how exactly subcutaneous adipocytes contribute to extracutaneous disease - and even influence important immune and brain functions! - is far from complete. The increasing insights recently won into subcutaneous adipose tissue as a cytokine depot that regulates innate immunity and cell growth exemplarily serve to illustrate the vast open research expanses that remain to be fully explored in the subcutis. The following public debate carries you from the evolutionary origins and the key functional purposes of adipose tissue, via adipose-derived stem cells and adipokines straight to the neuroendocrine, immunomodulatory and central nervous effects of signals that originate in the subcutis - perhaps, the most underestimated tissue of the human body. The editors are confident that, at the end, you shall agree: No basic scientist and no doctor with a serious interest in skin, and hardly anyone else in the life sciences, can afford to ignore the subcutaneous adipocyte - beyond its ample impact on beauty, benessence and body mass.

Published
2007

147. ESPEN Guidelines on Enteral Nutrition: Cardiology and pulmonology

Author

Anker, Sd, John, M, Pedersen, Pu, Raguso, C, Cicoira, Mariantonietta, Dardai, E, Laviano, A, Ponikowski, P, Schols, Am, DGEM GERMAN SOCIETY FOR NUTRITIONAL MEDICINE, Becker, Hf, Bohm, M, Brunkhorst, Fm, Vogelmeier, C, ESPEN EUROPEAN SOCIETY FOR PARENTERAL, and Enteral, Nutrition

Published
2006

149. Most children with eosinophilic esophagitis have a favorable outcome as young adults.

Author

Bohm, M., Jacobs Jr, J. W., Gupta, A., Gupta, S., and Wo, J. M.

Subjects
*EOSINOPHILIC esophagitis, *HEALTH of young adults, *CHILDREN'S health, *DISEASE progression, *DISEASE prevalence
Abstract

The disease progression of eosinophilic esophagitis (EoE) from childhood into adulthood is unclear. To determine the clinical outcome of patients who were diagnosed with EoE as children, and who now are young adults. Children (<18 years old) diagnosed with EoE were enrolled in a prospective registry on demographics, presenting symptoms, and endoscopic/histologic findings. Subjects who now are adults (=18 years old) were identified, and a structured telephone interview was conducted to obtain follow-up data on symptom prevalence (dysphagia to solids and liquids, nausea/vomiting, abdominal pain, and heartburn/regurgitation), food impaction, medication usage, health-care utilization, and resolution of atopy/food allergies. A favorable outcome was defined if EoE symptoms were resolved or improved by subjects' assessment. Unfavorable outcomes was defined as symptoms same or worse. Clinical variables that predicted a favorable outcome as an adult were examined. Mayo Dysphagia Scale (MDQ-30: scored 0-100) was administered to validate the outcome assessment. Mantel-Haenszel odds ratio and unpaired t-test were used. Fifty-eight subjects (64% male) who met study criteria were enrolled. Mean age at diagnosis was 12 years (range 4-17) and mean duration of follow-up was 8.3 years (2-16). As children, the most common presenting symptoms were abdominal pain (54%), dysphagia (33%), and vomiting (24%). As young adults, 47 subjects (81%) had a favorable outcome. Total MDQ-30 scores were 4.6 (0-30) and 14.1 (0-50) in subjects with favorable outcome and unfavorable outcome, respectively (P=0.015). Two-thirds of subjects did not use steroids or proton pump inhibitors in the preceeding 12 months. Male children with EoE were four times more likely to have a favorable outcome as young adults compared with female children. Females were more likely to report nausea/vomiting as young adults (odds ratio 3.23, CI 0.97-10.60). Of all presenting symptoms in EoE children, dysphagia was the most likely to persist into adulthood (odds ratio 6.29, CI 1.85-21.38). Eighty one percent of EoE children had a favorable outcome as young adults. Most patients with symptom resolution did not require any form of steroid therapy or seek healthcare. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

150. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology

Author

NIEMINEN MS., BOHM M., COWIE M., DREXLER H., FILIPPATOS G., JONDEAU G., HASIN Y., LOPEZSENDON J., MEBAZAA A., METRA M., RHODES A., SWEDBERG K., PRIORI S., GARCIA M., BLANC J., BUDAJ A., DEAN V., DECKERS J., BURGOS E., LEKAKIS J., LINDAHL B., MAZZOTTA G., MORAIS J., OTO A., SMISETH O., DICKSTEIN K., ALBUQUERQUE A., CONTHE P., CRESPO‐LEIRO M., FERRARI R., FOLLATH F., GAVAZZI A., JANSSENS U., KOMAJDA M., MORENO R., SINGER M., SINGH S., TENDERA M., THYGESEN K., and ESC COMMITTE FOR PRACTICE GUIDELINE (CPG)

Abstract

We found 1 article: Eur Heart J. 2005 Feb;26(4):384-416. Epub 2005 Jan 28. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Nieminen MS, Böhm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, Hasin Y, Lopez-Sendon J, Mebazaa A, Metra M, Rhodes A, Swedberg K, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie MR, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, Morais J, Oto A, Smiseth OA, Garcia MA, Dickstein K, Albuquerque A, Conthe P, Crespo-Leiro M, Ferrari R, Follath F, Gavazzi A, Janssens U, Komajda M, Morais J, Moreno R, Singer M, Singh S, Tendera M, Thygesen K; ESC Committe for Practice Guideline (CPG). Division of Cardiology, Helsinki University Central Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland. markku.nieminen@hus.fi PMID: 15681577 [PubMed - indexed for MEDLINE]Free Article

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results